首页 > 最新文献

Journal of Medical Imaging and Radiation Oncology最新文献

英文 中文
Abstract. 摘要
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-22 DOI: 10.1111/1754-9485.13758
{"title":"Abstract.","authors":"","doi":"10.1111/1754-9485.13758","DOIUrl":"https://doi.org/10.1111/1754-9485.13758","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation Oncology Orals 特刊:澳大利亚和新西兰皇家放射学院(RANZCR),第 74 届科学年会,2024 年 10 月 17-19 日。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-21 DOI: 10.1111/1754-9485.13780
{"title":"Radiation Oncology Orals","authors":"","doi":"10.1111/1754-9485.13780","DOIUrl":"10.1111/1754-9485.13780","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"68 S1","pages":"185-228"},"PeriodicalIF":2.2,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.13780","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation Oncology Exhibits 特刊:澳大利亚和新西兰皇家放射学院(RANZCR),第 74 届科学年会,2024 年 10 月 17-19 日。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-21 DOI: 10.1111/1754-9485.13779
{"title":"Radiation Oncology Exhibits","authors":"","doi":"10.1111/1754-9485.13779","DOIUrl":"10.1111/1754-9485.13779","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"68 S1","pages":"175-184"},"PeriodicalIF":2.2,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.13779","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Radiology Exhibits 特刊:澳大利亚和新西兰皇家放射学院(RANZCR),第 74 届科学年会,2024 年 10 月 17-19 日。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-21 DOI: 10.1111/1754-9485.13778
{"title":"Clinical Radiology Exhibits","authors":"","doi":"10.1111/1754-9485.13778","DOIUrl":"10.1111/1754-9485.13778","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"68 S1","pages":"67-174"},"PeriodicalIF":2.2,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.13778","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Radiology Oral 特刊:澳大利亚和新西兰皇家放射学院(RANZCR),第 74 届科学年会,2024 年 10 月 17-19 日。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-21 DOI: 10.1111/1754-9485.13777
{"title":"Clinical Radiology Oral","authors":"","doi":"10.1111/1754-9485.13777","DOIUrl":"10.1111/1754-9485.13777","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"68 S1","pages":"4-66"},"PeriodicalIF":2.2,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.13777","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma. 肝细胞癌经动脉治疗不彻底后单纯立体定向体放射治疗与立体定向体放射治疗的比较。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-20 DOI: 10.1111/1754-9485.13794
Youngju Song, Jinhong Jung, Jin-Hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Sang Min Yoon

Introduction: We investigated the clinical outcomes of stereotactic body radiation therapy (SBRT) alone versus SBRT after incomplete transarterial chemoembolization (TACE) for a single recurrent hepatocellular carcinoma (HCC) smaller than 5 cm.

Methods: We retrospectively reviewed the medical records of patients who underwent SBRT for a single recurrent HCC ≤5 cm, without vascular invasion or extrahepatic metastasis. Patients were divided into the SBRT-alone group and the TACE-SBRT group. The primary outcome was the local control (LC) rate, and secondary outcomes were survivals and treatment-related toxicities. We additionally conducted a propensity score matching (PSM) analysis.

Results: A total of 477 patients were available for analysis. Among them, 54 patients received SBRT without prior treatment to the target lesion (SBRT-alone group), whereas 423 patients received SBRT for viable HCC after TACE (TACE-SBRT group). The 3-year LC rates did not differ between the two groups (SBRT-alone group, 88.6% vs. TACE-SBRT group, 89.6%, P = 0.918). The 3-year rates of overall survival, out-of-field intrahepatic recurrence-free survival and recurrence-free survival were also not significantly different (P = 0.479, 0.290 and 0.273, respectively). Even after PSM, LC and survival rates at 3 years were not significantly different.

Conclusion: SBRT alone demonstrated comparable local control and survival outcomes to SBRT following incomplete TACE. SBRT alone may be considered an alternative treatment option for a single recurrent HCC smaller than 5 cm when curative treatments or TACE are not feasible.

简介我们研究了单纯立体定向体放射治疗(SBRT)与经动脉化疗栓塞术(TACE)治疗小于5厘米的单发复发性肝细胞癌(HCC)的临床疗效:我们回顾性地查看了因单发复发性肝细胞癌(HCC)小于5厘米、无血管侵犯或肝外转移而接受SBRT治疗的患者的病历。患者被分为SBRT单独组和TACE-SBRT组。主要结果是局部控制(LC)率,次要结果是存活率和治疗相关毒性反应。我们还进行了倾向评分匹配(PSM)分析:共有 477 例患者可供分析。其中,54 例患者在未对靶病灶进行治疗的情况下接受了 SBRT 治疗(SBRT-单独组),而 423 例患者在 TACE 后接受了针对存活 HCC 的 SBRT 治疗(TACE-SBRT 组)。两组患者的3年生存率没有差异(SBRT-alone组88.6% vs. TACE-SBRT组89.6%,P = 0.918)。3年总生存率、场外肝内无复发生存率和无复发生存率也无显著差异(P = 0.479、0.290 和 0.273)。即使在 PSM 后,LC 和 3 年生存率也无明显差异:结论:单纯 SBRT 与不完全 TACE 后的 SBRT 的局部控制和生存率相当。在无法进行根治性治疗或 TACE 的情况下,对于小于 5 厘米的单发复发性 HCC,单用 SBRT 可被视为一种替代治疗方案。
{"title":"Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma.","authors":"Youngju Song, Jinhong Jung, Jin-Hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Sang Min Yoon","doi":"10.1111/1754-9485.13794","DOIUrl":"https://doi.org/10.1111/1754-9485.13794","url":null,"abstract":"<p><strong>Introduction: </strong>We investigated the clinical outcomes of stereotactic body radiation therapy (SBRT) alone versus SBRT after incomplete transarterial chemoembolization (TACE) for a single recurrent hepatocellular carcinoma (HCC) smaller than 5 cm.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of patients who underwent SBRT for a single recurrent HCC ≤5 cm, without vascular invasion or extrahepatic metastasis. Patients were divided into the SBRT-alone group and the TACE-SBRT group. The primary outcome was the local control (LC) rate, and secondary outcomes were survivals and treatment-related toxicities. We additionally conducted a propensity score matching (PSM) analysis.</p><p><strong>Results: </strong>A total of 477 patients were available for analysis. Among them, 54 patients received SBRT without prior treatment to the target lesion (SBRT-alone group), whereas 423 patients received SBRT for viable HCC after TACE (TACE-SBRT group). The 3-year LC rates did not differ between the two groups (SBRT-alone group, 88.6% vs. TACE-SBRT group, 89.6%, P = 0.918). The 3-year rates of overall survival, out-of-field intrahepatic recurrence-free survival and recurrence-free survival were also not significantly different (P = 0.479, 0.290 and 0.273, respectively). Even after PSM, LC and survival rates at 3 years were not significantly different.</p><p><strong>Conclusion: </strong>SBRT alone demonstrated comparable local control and survival outcomes to SBRT following incomplete TACE. SBRT alone may be considered an alternative treatment option for a single recurrent HCC smaller than 5 cm when curative treatments or TACE are not feasible.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amputation and limb-sparing surgery in childhood sarcoma: Post-operative imaging appearances and complications. 儿童肉瘤的截肢和保肢手术:术后影像学表现和并发症。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-20 DOI: 10.1111/1754-9485.13790
Joel Earley, Derek Roebuck

Limb-sparing surgery and amputation are common surgical techniques used to achieve local tumour control in childhood primary bone and soft tissue malignancy of the limbs. The interpretation of post-operative limb imaging in these frequently complex cases is assisted by knowledge of the surgical techniques employed. This review discusses the rationale underpinning the most common surgical techniques used for these patients as well as their expected post-operative imaging appearance and complications. Amputation, long bone resection, endoprosthetic reconstruction, allograft reconstruction, the use of fibular autografts, allograft-prosthetic composite reconstruction and arthrodesis are discussed.

保肢手术和截肢是儿童原发性肢体骨与软组织恶性肿瘤实现局部肿瘤控制的常用手术技术。在这些复杂的病例中,对术后肢体成像的解读需要了解所采用的手术技术。本综述讨论了这些患者最常用的手术技术的基本原理,以及术后预期的影像学表现和并发症。文中讨论了截肢、长骨切除、假体内重建、同种异体重建、腓骨自体移植物的使用、同种异体移植物-假体复合重建和关节置换术。
{"title":"Amputation and limb-sparing surgery in childhood sarcoma: Post-operative imaging appearances and complications.","authors":"Joel Earley, Derek Roebuck","doi":"10.1111/1754-9485.13790","DOIUrl":"https://doi.org/10.1111/1754-9485.13790","url":null,"abstract":"<p><p>Limb-sparing surgery and amputation are common surgical techniques used to achieve local tumour control in childhood primary bone and soft tissue malignancy of the limbs. The interpretation of post-operative limb imaging in these frequently complex cases is assisted by knowledge of the surgical techniques employed. This review discusses the rationale underpinning the most common surgical techniques used for these patients as well as their expected post-operative imaging appearance and complications. Amputation, long bone resection, endoprosthetic reconstruction, allograft reconstruction, the use of fibular autografts, allograft-prosthetic composite reconstruction and arthrodesis are discussed.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A keep-it-simple embolisation approach to treat pelvic congestion syndrome without compromising clinical effectiveness. 治疗盆腔充血综合征的简便栓塞法不会影响临床疗效。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-20 DOI: 10.1111/1754-9485.13795
Eisen Liang, Wai Yan Timothy Wong, Razeen Parvez, Michael Chan, Bevan Brown

Introduction: There are two approaches to treating pelvic congestion syndrome (PCS): (i) the keep-it-simple (KIS) approach, which involves embolising only the refluxing vein(s), typically the left ovarian vein (LOV) unless the right ovarian vein (ROV) or left/right internal iliac vein (IIV) tributaries are also refluxing; and (ii) the extensive (EXT) approach, which empirically embolises almost all of the LOV, ROV, and left and right IIV tributaries. The aim of this study is to determine whether the KIS approach can effectively treat PCS while minimising the number of treated veins and coils used, without the need for injecting sclerosing agents into pelvic veins or the use of occlusion balloons.

Methods: This is a single-institution retrospective cohort study. Our records identified 154 women who underwent venograms for possible PCS, with the intent to proceed with embolisation. Refluxing veins were treated using the KIS approach, deploying minimal number of coils, 'sandwiching' sclerosing foam. Short-term follow-up was conducted at 6 weeks; long-term follow-ups (between 12 and 60 months) were conducted via an electronic survey consisting of 19 questions assessing pelvic pain/pressure, leg and back pain, fatigue, and bladder and menstrual symptoms.

Results: Fifteen women had negative venogram; 139 women had one or more refluxing veins on venogram. Most women (73%) required unilateral ovarian vein (OV) embolisation, 14% required bilateral OV embolisation, and 12% underwent pelvic vein embolisation. Most cases required only four pushable coils. Clinical success was 89% at 6 weeks and 84% at 1-5 years. A visual analogue scale reduction of 5.2 points (from 7.8 to 2.7) was achieved. There were no instances of coil dislodgement or other complications.

Conclusion: The keep-it-simple approach, embolising only the refluxing ovarian and/or iliac veins, can achieve a successful clinical outcome for pelvic congestion syndrome. The extensive approach of empirically embolising all ovarian veins and internal iliac veins may not be necessary. This carries implications for potential savings in procedure time, cost and radiation dose.

简介:治疗盆腔充血综合征(PCS)有两种方法:(i) 保持简单(KIS)法,即只栓塞反流的静脉,通常是左卵巢静脉(LOV),除非右卵巢静脉(ROV)或左/右髂内静脉(IIV)支流也出现反流;(ii) 广泛(EXT)法,即根据经验栓塞几乎所有的左卵巢静脉、右卵巢静脉、左/右髂内静脉支流。本研究旨在确定 KIS 方法能否有效治疗 PCS,同时最大限度地减少治疗静脉和所用线圈的数量,而无需向盆腔静脉注射硬化剂或使用闭塞球囊:这是一项单一机构的回顾性队列研究。方法:这是一项单一机构的回顾性队列研究。我们的记录显示,有 154 名妇女因可能的 PCS 而接受了静脉造影检查,并打算进行栓塞治疗。反流静脉采用 KIS 方法进行治疗,在 "夹心 "硬化剂泡沫中植入最少数量的线圈。短期随访6周;长期随访(12至60个月)通过电子调查进行,调查包括19个问题,评估骨盆疼痛/压力、腿部和背部疼痛、疲劳、膀胱和月经症状:15名妇女的静脉造影结果为阴性;139名妇女的静脉造影结果为一条或多条回流静脉。大多数妇女(73%)需要进行单侧卵巢静脉栓塞术,14%需要进行双侧卵巢静脉栓塞术,12%进行盆腔静脉栓塞术。大多数病例只需要四个可推动线圈。6周时的临床成功率为89%,1-5年时为84%。视觉模拟评分减少了 5.2 分(从 7.8 分减少到 2.7 分)。没有发生线圈脱落或其他并发症:结论:仅对反流的卵巢和/或髂静脉进行栓塞的 "简单易行 "方法可使盆腔充血综合征的临床治疗取得成功。对所有卵巢静脉和髂内静脉进行经验性栓塞的广泛方法可能没有必要。这可能会节省手术时间、费用和辐射剂量。
{"title":"A keep-it-simple embolisation approach to treat pelvic congestion syndrome without compromising clinical effectiveness.","authors":"Eisen Liang, Wai Yan Timothy Wong, Razeen Parvez, Michael Chan, Bevan Brown","doi":"10.1111/1754-9485.13795","DOIUrl":"https://doi.org/10.1111/1754-9485.13795","url":null,"abstract":"<p><strong>Introduction: </strong>There are two approaches to treating pelvic congestion syndrome (PCS): (i) the keep-it-simple (KIS) approach, which involves embolising only the refluxing vein(s), typically the left ovarian vein (LOV) unless the right ovarian vein (ROV) or left/right internal iliac vein (IIV) tributaries are also refluxing; and (ii) the extensive (EXT) approach, which empirically embolises almost all of the LOV, ROV, and left and right IIV tributaries. The aim of this study is to determine whether the KIS approach can effectively treat PCS while minimising the number of treated veins and coils used, without the need for injecting sclerosing agents into pelvic veins or the use of occlusion balloons.</p><p><strong>Methods: </strong>This is a single-institution retrospective cohort study. Our records identified 154 women who underwent venograms for possible PCS, with the intent to proceed with embolisation. Refluxing veins were treated using the KIS approach, deploying minimal number of coils, 'sandwiching' sclerosing foam. Short-term follow-up was conducted at 6 weeks; long-term follow-ups (between 12 and 60 months) were conducted via an electronic survey consisting of 19 questions assessing pelvic pain/pressure, leg and back pain, fatigue, and bladder and menstrual symptoms.</p><p><strong>Results: </strong>Fifteen women had negative venogram; 139 women had one or more refluxing veins on venogram. Most women (73%) required unilateral ovarian vein (OV) embolisation, 14% required bilateral OV embolisation, and 12% underwent pelvic vein embolisation. Most cases required only four pushable coils. Clinical success was 89% at 6 weeks and 84% at 1-5 years. A visual analogue scale reduction of 5.2 points (from 7.8 to 2.7) was achieved. There were no instances of coil dislodgement or other complications.</p><p><strong>Conclusion: </strong>The keep-it-simple approach, embolising only the refluxing ovarian and/or iliac veins, can achieve a successful clinical outcome for pelvic congestion syndrome. The extensive approach of empirically embolising all ovarian veins and internal iliac veins may not be necessary. This carries implications for potential savings in procedure time, cost and radiation dose.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative analysis of clinical treatment outcomes: Breath-hold vs. free-breathing techniques in liver stereotactic body radiotherapy. 临床治疗效果对比分析:肝脏立体定向体放射治疗中的屏气与自由呼吸技术。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-20 DOI: 10.1111/1754-9485.13793
Kosuke Morishima, Hideomi Yamashita, Tomoyuki Noyama, Atsuto Katano

Introduction: The aim of this study was to clarify the safety and efficacy of breath-hold irradiation in liver stereotactic body radiotherapy (SBRT).

Methods: A retrospective analysis was conducted on 57 consecutive patients who received SBRT for hepatocellular carcinoma or liver metastases between 2013 and 2021. Breath-hold irradiation was implemented for patients treated after April 2020.

Results: The median follow-up period for all patients was 16.4 months (IQR: 7.36-20.9). The 2-year overall survival rate was 64.4% (95% CI: 47.4-77.2), and the local control rate was 84.3% (95% CI: 69.7-92.3) for all patients. The 1-year overall survival was 80.0% (95% CI: 60.8-90.5) versus 82.0% (95% CI: 53.5-93.9) in the free-respiratory (FR) group versus the breath-hold (BH) group, respectively (P = 0.60). The 1-year local control rates were 78.1% (95% CI: 57.5-89.5) in the FR group and 95.7% (95% CI: 72.9-99.4) in the BH group, respectively (P = 0.16). Radiation-induced liver injury, defined by an escalation of ≥2 in Child-Pugh score, was observed in four patients within each group (FR 13% vs. BH 15%). There were no gastrointestinal adverse events of Grade 3 or higher.

Conclusion: Breath-hold irradiation can be safely administered and has demonstrated clinical potential in improving local control. Further research into dose escalation using breath-hold techniques is warranted.

导言本研究旨在明确屏气照射在肝脏立体定向体放射治疗(SBRT)中的安全性和有效性:方法:对2013年至2021年间连续接受SBRT治疗肝细胞癌或肝转移的57例患者进行了回顾性分析。结果:所有患者的中位随访期均为2年:所有患者的中位随访时间为16.4个月(IQR:7.36-20.9)。所有患者的2年总生存率为64.4%(95% CI:47.4-77.2),局部控制率为84.3%(95% CI:69.7-92.3)。自由呼吸(FR)组与屏气(BH)组的1年总生存率分别为80.0%(95% CI:60.8-90.5)和82.0%(95% CI:53.5-93.9)(P = 0.60)。自由呼吸组和屏气组的 1 年局部控制率分别为 78.1%(95% CI:57.5-89.5)和 95.7%(95% CI:72.9-99.4)(P = 0.16)。各组中均有四名患者观察到辐射诱导的肝损伤,定义为 Child-Pugh 评分≥2 分(FR 组 13% 对 BH 组 15%)。没有出现3级或以上的胃肠道不良反应:结论:屏气照射可以安全实施,在改善局部控制方面具有临床潜力。使用屏气技术进行剂量升级的进一步研究是有必要的。
{"title":"Comparative analysis of clinical treatment outcomes: Breath-hold vs. free-breathing techniques in liver stereotactic body radiotherapy.","authors":"Kosuke Morishima, Hideomi Yamashita, Tomoyuki Noyama, Atsuto Katano","doi":"10.1111/1754-9485.13793","DOIUrl":"https://doi.org/10.1111/1754-9485.13793","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to clarify the safety and efficacy of breath-hold irradiation in liver stereotactic body radiotherapy (SBRT).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 57 consecutive patients who received SBRT for hepatocellular carcinoma or liver metastases between 2013 and 2021. Breath-hold irradiation was implemented for patients treated after April 2020.</p><p><strong>Results: </strong>The median follow-up period for all patients was 16.4 months (IQR: 7.36-20.9). The 2-year overall survival rate was 64.4% (95% CI: 47.4-77.2), and the local control rate was 84.3% (95% CI: 69.7-92.3) for all patients. The 1-year overall survival was 80.0% (95% CI: 60.8-90.5) versus 82.0% (95% CI: 53.5-93.9) in the free-respiratory (FR) group versus the breath-hold (BH) group, respectively (P = 0.60). The 1-year local control rates were 78.1% (95% CI: 57.5-89.5) in the FR group and 95.7% (95% CI: 72.9-99.4) in the BH group, respectively (P = 0.16). Radiation-induced liver injury, defined by an escalation of ≥2 in Child-Pugh score, was observed in four patients within each group (FR 13% vs. BH 15%). There were no gastrointestinal adverse events of Grade 3 or higher.</p><p><strong>Conclusion: </strong>Breath-hold irradiation can be safely administered and has demonstrated clinical potential in improving local control. Further research into dose escalation using breath-hold techniques is warranted.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review of extrahepatic hepatic artery pseudoaneurysm following adult liver transplantation: Risk factors and treatment modalities. 成人肝移植术后肝外动脉假性动脉瘤的系统回顾:风险因素和治疗方法。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-20 DOI: 10.1111/1754-9485.13745
Ryan Pereira, Benjamin J Pearch, Gilbert Pavilion, Kheman Rajkomar

Hepatic artery pseudoaneurysm (HAP) is a rare vascular complication following liver transplantation (LTx) with treatment choice frequently driven by institutional experience. Approximately, 10% of hepatic grafts are lost from this complication, requiring re-transplantation and placing further demand on the already present organ shortage. Secondly, patients with HAP can present with catastrophic bleeding, with reported mortality of up to 78%. We aim to identify risk factors associated with HAP and assess the survival benefit of different treatment modalities used (endovascular and open surgical techniques). Early detection may facilitate semi-elective management of this condition. A systematic search was performed in PubMed, Medline and Embase up to 1 October 2023. Case series with ≥5 patients focusing on adult patients who developed extrahepatic pseudoaneurysm following LTx were included. A total of 11 studies were pooled, comprising of 118 patients with survival data available in 61 patients. The most common presentation was haemorrhagic shock or luminal haemorrhage (75.5%). Bile leak was documented in 66.7% (28/42), 15.2% (18/118) associated foregut pathologies and 28.6% (14/49) of microbiology cultures grew a fungal organism. Flow preserving strategies (stenting, revascularization) trended towards better survival at 120 months compared to non-flow preserving strategies (embolization, HAL); however, this was not statistically significant following log rank (Mantel-Cox) analysis (P 0.169). Any patient following LTx presenting with haemorrhagic shock or luminal bleeding needs HAP excluded urgently. HAP management is complex, requiring careful consideration of patient specific presentation, anatomic factors and associated pathologies.

肝动脉假性动脉瘤(HAP)是肝移植(LTx)术后一种罕见的血管并发症,治疗方法的选择往往取决于医疗机构的经验。大约有 10% 的肝移植物会因这种并发症而丢失,需要重新移植,从而进一步加剧了本已短缺的器官的需求。其次,HAP 患者可能出现灾难性出血,据报道死亡率高达 78%。我们的目标是确定与 HAP 相关的风险因素,并评估不同治疗方式(血管内和开放手术技术)对患者生存的益处。早期发现可促进对这种疾病的半选择性治疗。截至 2023 年 10 月 1 日,我们在 PubMed、Medline 和 Embase 中进行了系统性检索。研究纳入了患者人数≥5人的病例系列,主要关注LTx术后出现肝外假性动脉瘤的成年患者。共汇总了11项研究,包括118名患者,其中61名患者有生存数据。最常见的表现是失血性休克或腔内出血(75.5%)。66.7%(28/42)的患者有胆漏记录,15.2%(18/118)的患者伴有前肠病变,28.6%(14/49)的微生物培养结果为真菌。与非血流保护策略(栓塞、HAL)相比,血流保护策略(支架植入、血管再通)的120个月存活率呈上升趋势;但对数秩(Mantel-Cox)分析显示,这并无统计学意义(P 0.169)。任何LTx术后出现失血性休克或管腔出血的患者都急需排除HAP。HAP 的处理非常复杂,需要仔细考虑患者的具体表现、解剖因素和相关病理。
{"title":"Systematic review of extrahepatic hepatic artery pseudoaneurysm following adult liver transplantation: Risk factors and treatment modalities.","authors":"Ryan Pereira, Benjamin J Pearch, Gilbert Pavilion, Kheman Rajkomar","doi":"10.1111/1754-9485.13745","DOIUrl":"https://doi.org/10.1111/1754-9485.13745","url":null,"abstract":"<p><p>Hepatic artery pseudoaneurysm (HAP) is a rare vascular complication following liver transplantation (LTx) with treatment choice frequently driven by institutional experience. Approximately, 10% of hepatic grafts are lost from this complication, requiring re-transplantation and placing further demand on the already present organ shortage. Secondly, patients with HAP can present with catastrophic bleeding, with reported mortality of up to 78%. We aim to identify risk factors associated with HAP and assess the survival benefit of different treatment modalities used (endovascular and open surgical techniques). Early detection may facilitate semi-elective management of this condition. A systematic search was performed in PubMed, Medline and Embase up to 1 October 2023. Case series with ≥5 patients focusing on adult patients who developed extrahepatic pseudoaneurysm following LTx were included. A total of 11 studies were pooled, comprising of 118 patients with survival data available in 61 patients. The most common presentation was haemorrhagic shock or luminal haemorrhage (75.5%). Bile leak was documented in 66.7% (28/42), 15.2% (18/118) associated foregut pathologies and 28.6% (14/49) of microbiology cultures grew a fungal organism. Flow preserving strategies (stenting, revascularization) trended towards better survival at 120 months compared to non-flow preserving strategies (embolization, HAL); however, this was not statistically significant following log rank (Mantel-Cox) analysis (P 0.169). Any patient following LTx presenting with haemorrhagic shock or luminal bleeding needs HAP excluded urgently. HAP management is complex, requiring careful consideration of patient specific presentation, anatomic factors and associated pathologies.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Medical Imaging and Radiation Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1